1. Volume 16, Issue 8, Pages 928-936 (August 2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial 
Prof Amit M Oza, MD, Adrian D Cook, MSc, Prof Jacobus Pfisterer, MD, Andrew Embleton, MSc, Prof Jonathan A Ledermann, MD, Prof Eric Pujade-Lauraine, MD, Prof Gunnar Kristensen, PhD, Mark S Carey, MD, Philip Beale, MD, Prof Andrés Cervantes, MD, Prof Tjoung- Won Park-Simon, MD, Prof Gordon Rustin, MD, Prof Florence Joly, MD, Mansoor R Mirza, MD, Marie Plante, MD, Prof Michael Quinn, MD, Andrés Poveda, MD, Prof Gordon C Jayson, PhD, Dan Stark, MD, Prof Ann Marie Swart, MBBS, Laura Farrelly, MSc, Prof Richard Kaplan, MD, Prof Mahesh K B Parmar, PhD, Prof Timothy J Perren, MD 
The Lancet Oncology 
Volume 16, Issue 8, Pages (August 2015)
DOI: /S (15)
Copyright © 2015 Oza et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
*Includes 16 patients last seen more than 6 months before the end of the study. †Includes 11 patients last seen more than 6 months before the end of the study.
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Oza et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2 Overall survival
(A) Overall survival in all patients. (B) Difference in overall survival between all patients in the two groups. (C) Overall survival in high-risk patients. (D) Difference in overall survival between high-risk patients in the two groups.
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Oza et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3
Treatment effect on overall survival by disease status at enrolment
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Oza et al. Open Access article distributed under the terms of CC BY Terms and Conditions